CXCL8 and renal cell carcinoma: Nonetheless, consistent with our results, other studies have shown that IL-8 mediates acquired resistance to another VEGFR TKI, sunitinib, in preclinical models of renal cell carcinoma; neutralizing IL-8 with anti-IL-8 antibody reversed the resistance to sunitinib [22].